6 x ROHM Letrozole 2.5mg x 50

Description

Classification

Product: 6 x ROHM Letrozole 2.5mg x 50
Brand: ROHM
Active ingredient: Letrozole, subject to product-label verification
Strength: 2.5mg per tablet
Pack size: 50 tablets
Bulk quantity: 6 packs
Total tablets: 300
Product type: Aromatase inhibitor / oral tablet

Letrozole is a non-steroidal aromatase inhibitor that reduces the body’s production of oestrogen. Current UK medicines information lists authorised 2.5mg letrozole tablets as prescription-only medicines.

The specific ROHM-branded product should not automatically be considered identical to an authorised UK pharmaceutical product. Its formulation, manufacturing standards, tablet contents and regulatory status should be confirmed from the current packaging and batch documentation.

What is 6 x ROHM Letrozole 2.5mg x 50?

6 x ROHM Letrozole 2.5mg x 50 is a bulk listing containing six packs of 50 tablets, giving a total of 300 tablets. Each tablet is labelled at 2.5mg.

Letrozole works by inhibiting the aromatase enzyme, which is responsible for converting certain androgens into oestrogens. By reducing oestrogen production, letrozole produces a strong reduction in circulating oestrogen levels.

In the UK, authorised letrozole 2.5mg medicines are principally indicated for specific forms of hormone-dependent breast cancer in postmenopausal women.

Dosage

For authorised UK letrozole medicines, the standard recommended dose for the licensed breast-cancer indications is 2.5mg once daily.

However, this information should not be interpreted as a recommended regimen for ROHM Letrozole 2.5mg x 50. The specific ROHM product’s formulation and regulatory status should first be verified.

Letrozole should not be self-administered simply to manipulate oestrogen levels, manage steroid-related effects or construct a bodybuilding/PCT protocol. Excessive suppression of oestrogen can itself cause significant health problems.

How Does ROHM Letrozole 2.5mg Work?

Letrozole inhibits aromatase, an enzyme involved in the conversion of androgens into oestrogens.

Reducing aromatase activity substantially decreases oestrogen synthesis. This mechanism is particularly important in hormone receptor-positive breast cancer, where lowering oestrogen can reduce hormonal stimulation of tumour cells.

In people who rely on oestrogen for normal physiological function, excessive suppression can produce unwanted effects involving bone, joints, lipids, mood and sexual health.

Potential Benefits

When appropriately prescribed for its licensed indications, letrozole can reduce oestrogen production and help manage hormone-dependent breast cancer.

Current UK product information includes adjuvant treatment of postmenopausal women with hormone receptor-positive early breast cancer, extended adjuvant treatment following tamoxifen, first-line treatment of advanced hormone-dependent breast cancer and certain neoadjuvant settings.

These established medical uses should not be confused with informal use of letrozole for bodybuilding, PCT or controlling oestrogen-related symptoms without medical supervision.

When Should You Not Take ROHM Letrozole 2.5mg?

Letrozole may be unsuitable for people with certain medical conditions.

Authorised product information identifies important contraindications including:

• Pregnancy
• Breast-feeding
• Premenopausal endocrine status for the licensed breast-cancer indication
• Known hypersensitivity to letrozole or formulation ingredients

Additional medical assessment may be required in people with liver disease, kidney impairment, osteoporosis or other conditions affected by prolonged oestrogen reduction.

Women of potentially child-bearing age require particular consideration because letrozole can cause fetal harm.

Mechanism

Aromatase is an enzyme involved in the final stages of oestrogen biosynthesis.

Letrozole binds to and inhibits aromatase, reducing the conversion of androgen precursors into oestradiol and other oestrogens. This produces a substantial reduction in oestrogen availability.

In postmenopausal women, peripheral tissues are an important source of oestrogen production, making aromatase inhibition particularly useful in hormone-dependent breast cancer.

Because oestrogen also contributes to bone maintenance and other normal physiological functions, excessive or prolonged suppression can have clinically important consequences.

Uses

Authorised UK letrozole medicines are used primarily for hormone-dependent breast cancer in postmenopausal women.

Approved indications include adjuvant treatment of hormone receptor-positive early breast cancer, extended adjuvant treatment after tamoxifen, first-line treatment of advanced hormone-dependent breast cancer and certain neoadjuvant situations.

Letrozole is sometimes discussed online in connection with fertility treatment or management of steroid-associated oestrogen effects. Such uses should not be confused with the licensed indications of UK-authorised products and require appropriate specialist assessment.

Warnings and Precautions

Strong aromatase inhibition can produce very low oestrogen concentrations.

Potential consequences include joint and musculoskeletal symptoms, reduced bone mineral density and changes in lipid metabolism. Long-term treatment may therefore require appropriate clinical monitoring.

Letrozole may also cause dizziness and fatigue, which can affect activities requiring concentration. Current product information advises caution where these effects occur.

Drug interactions should be reviewed by a healthcare professional before treatment, particularly when other prescription medicines are being taken.

Side Effects

Potential adverse effects associated with letrozole include:

• Hot flushes
• Increased sweating
• Joint or musculoskeletal pain
• Fatigue
• Headache
• Dizziness
• Nausea
• Increased cholesterol
• Reduced bone mineral density
• Mood changes
• Sleep disturbance
• Vaginal dryness
• Changes in appetite or body weight

Long-term reduction of oestrogen can increase the risk of osteoporosis and fractures. The precise adverse-effect profile depends on treatment duration, patient characteristics and the underlying condition.

Storage

Store 6 x ROHM Letrozole 2.5mg x 50 according to the manufacturer’s current storage instructions.

Authorised letrozole products are generally kept in their original packaging, with the medicine protected appropriately and kept out of the sight and reach of children.

Do not use tablets after their stated expiry date or if the packaging has been damaged or the tablets appear abnormal.

Where to Buy 6 x ROHM Letrozole 2.5mg x 50?

To get 6 x ROHM Letrozole 2.5mg x 50 Tablets online, go to Steroid Sanctuary today to get the best deal on this medicine.

Frequently Asked Questions

1. What is 6 x ROHM Letrozole 2.5mg x 50?

It is a bulk listing containing six packs of 50 tablets, giving a total of 300 tablets, with each tablet labelled at 2.5mg.

2. What is letrozole?

Letrozole is a non-steroidal aromatase inhibitor that reduces the production of oestrogen. It is available as prescription-only 2.5mg tablets in the UK.

3. What is letrozole used for?

Authorised UK products are primarily used for several forms of hormone-dependent breast cancer in postmenopausal women, including adjuvant, extended adjuvant and advanced disease settings.

4. Is 2.5mg the standard strength of letrozole?

Yes. Current UK-authorised letrozole tablets contain 2.5mg letrozole per tablet, and the recommended dose for the licensed breast-cancer indications is generally 2.5mg once daily.

5. How many tablets are included in 6 x ROHM Letrozole 2.5mg x 50?

The bulk listing contains 6 x 50 tablets, giving a total of 300 tablets.